Ossiam Increases Holdings in Axon Enterprise, Inc $AXON

Ossiam boosted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 10.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,943 shares of the biotechnology company’s stock after purchasing an additional 2,161 shares during the period. Ossiam’s holdings in Axon Enterprise were worth $16,465,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. grew its stake in Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital increased its holdings in shares of Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC lifted its position in shares of Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Axon Enterprise by 2.5% during the third quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 16 shares during the period. Finally, NorthCrest Asset Manangement LLC boosted its holdings in shares of Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 16 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AXON has been the topic of a number of research analyst reports. Craig Hallum reaffirmed a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. Piper Sandler lowered their price target on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Morgan Stanley dropped their price target on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, UBS Group cut their price objective on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Stock Performance

AXON stock opened at $496.18 on Friday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $39.89 billion, a price-to-earnings ratio of 326.44, a P/E/G ratio of 10.66 and a beta of 1.46. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91. The firm has a 50 day moving average of $531.08 and a two-hundred day moving average of $610.44.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same quarter in the prior year, the business posted $2.08 EPS. Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the sale, the chief executive officer owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. This represents a 0.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 24,634 shares of company stock valued at $13,803,095 over the last three months. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.